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a b s t r a c t
Despite advances in our understanding of the mechanisms involved in sex determination and differ-
entiation, the speciﬁc roles of many genes in these processes are not completely understood in humans.
Both DMRT1 and FGF9 are among this group of genes. Dmrt1 controls germ cell differentiation, prolif-
eration, migration and pluripotency and Sertoli cell proliferation and differentiation. Fgf9 has been
considered a critical factor in early testicular development and germ cell survival in mice. We screened
for the presence of DMRT1 and FGF9 mutations in 33 patients with 46,XY gonadal dysgenesis. No
deletions in either DMRT1 or FGF9 were identiﬁed using the MLPA technique. Eight allelic variants of
DMRT1 were identiﬁed, and in silico analysis suggested that the novel c.968-15insTTCTCTCT variant and
the c.774G>C (rs146975077) variant could have potentially deleterious effects on the DMRT1 protein.
Nine previously described FGF9 allelic variants and six different alleles of the 3’ UTR microsatellite were
identiﬁed. However, none of these DMRT1 or FGF9 variants was associated with increased 46,XY gonadal
dysgenesis. In conclusion, our study suggests that neither DMRT1 nor FGF9 abnormalities are frequently
involved in dysgenetic male gonad development in patients with non-syndromic 46,XY disorder of sex
development.
 2012 Published by Elsevier Masson SAS.
1. Introduction
Sex determination in mammals is a dynamic process in which
germ and somatic cells acquire sex-speciﬁc characteristics. In
humans, the bipotential embryonic gonad begins to develop
around the ﬁfth week of foetal life [1]. In the 6th and 7th weeks, the
differentiation of speciﬁc cell groups in the bipotential gonadal
tissue occurs; this will determine the development of the ovaries or
testes, two very different organs with specialised functions [2].
Despite advances in our knowledge of the mechanisms involved
in sex determination and differentiation, the exact roles of many
genes that participate in different stages of this complex process are
not completely understood [2]. Both DMRT1 and FGF9 genes are
among this group of genes. Several studies have shown evidence of
their roles in testicular development in mice, but their exact
functions in the human testis have not been established [3,4]
TheDMRT1 (Doublesex andmab-3-related transcription factor 1)
gene, amember of theDMRT family, plays diverse and essential roles
in vertebrate testis development. In the mouse testis, Dmrt1 is
suggested to control germ cell differentiation, proliferation, migra-
tion and pluripotency and Sertoli cell proliferation and differentia-
tion [3,5]. In female gonads, Dmrt1 directly regulates Stra8
transcription and is involved in the postnatal formation of ovarian
follicles [6].
More recently, it has been suggested that Dmrt1 is involved in
maintaining male fate in mammals after birth, suppressing female
gonad development pathways in the male gonad by antagonising
Foxl2 [6,7]. This represents a new and important function for Dmrt1
in the male gonads after birth.
In humans, the deletion of DMRT1 has been rarely associated
with the presence of isolated gonadal dysgenesis in 46,XY DSD
patients [8,9].
The FGF9 (Fibroblast Growth Factor 9) gene, a member of the
ﬁbroblast growth factor family, has been considered a critical factor
in early testicular development and germ cell survival in mice [4].
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Recently, a new model of gene interaction was proposed to explain
the activities of the Sox9/Fgf9 versus Wnt4/Rspo1 genes in gonadal
development. In this model, Sox9 up-regulates Fgf9 expression,
which maintains Fgf9 and Sox9 expression through a positive
feedback mechanism. In this situation, the balance between Fgf9
andWnt4 signals favours Fgf9, establishing the male pathway. Both
Sox9 and Fgf9 knockout XY mice show sex reversal as a conse-
quence of the inhibition of masculinising events in the embryonic
gonad [10]. Fgf9 mutant mice die soon after birth due to lung
defects, but the XY embryos also had abnormalities in gonadal
development similar to those observed in patients with 46,XY
gonadal dysgenesis [11].
We screened for the presence of DMRT1 and FGF9 mutations in
a large cohort of patients with 46,XYgonadal dysgenesis to evaluate
the possible disruption of their function in these patients.
2. Materials and methods
2.1. Patients
This study was approved by the Ethics Committee of the
Hospital das Clinicas da Faculdade de Medicina da Universidade de
Sao Paulo, and written informed consent was obtained from all
patients or their legal guardians.
Thirty-three patients with 46,XY disorder of sex development
(DSD) due to abnormal gonadal development who were receiving
treatment at the Unit of Endocrinology of the Development of
Hospital das Clinicas were studied. Eleven patients presented
complete gonadal dysgenesis (CGD), and 22 patients presented
partial gonadal dysgenesis (PGD).
Subjects with mutations in the SRY, SF1, GATA4, or DHH genes or
gene dosage imbalance in the DAX1 or WNT4 genes were excluded
from the study.
2.2. Molecular analysis
Genomic DNA was extracted from peripheral blood leukocytes
using the proteinase K-SDS salting-out method [12].
2.3. MLPA (Multiplex ligation probe ampliﬁcation)
MLPA analysis of DMRT1 was carried out using the commercial
P334-A1 Gonadal Development Disorder Kit (MCR Holland,
Amsterdam, The Netherlands). This kit contains 10 probes for the
DMRT1 gene (2 probes for each of the 5 exons of DMRT1) in addition
to probes for the CYP17A, SRD5A2 and HSD17b3 genes and control
probes.
MLPA analysis of FGF9 was carried out using in-house FGF9
probes partially covering the coding region of the gene and four
control synthetic probes (GABRA4, MPDZ, RB1 and UHRF2, located at
chromosomes 4p12, 9p23, 13q14.2 and 9p24.1, respectively) [13e
15]. The MLPA reactions were carried out using the in-house
probe set and the reagents from P231 reagent kit. The MLPA
probe sequences are described in Table 1. The results were analysed
using Genescan 3.7 and further evaluated using Excel (Microsoft).
2.4. DMRT1 and FGF9 direct sequencing
The entire DMRT1 (NM_021951.2/ENSG00000137090) and FGF9
(NM_002010/ENST00000382353) coding region and the exone
intron boundary areas were PCR-ampliﬁed using speciﬁc primers.
The primers used for DMRT1 were previously described by Vinci
et al. [16], and FGF9 primers were designed using the Primer3
program (http://frodo.wi.mi.edu).
The PCR products were puriﬁed with “ExoSAP-IT” (GE Health-
care Life Sciences, Buckinghamshire, UK) and sequenced using the
standard dideoxy chain termination method with the ABI Prism
BigDye Terminator Cycle Sequencing Ready Reaction Kit 3.1 (Life
Technologies, Foster City, CA, USA). Control DNA samples were
obtained from 89 fertile males.
Variant sequences of the FGF9 3’ UTR, (GA)3(AG)2(GA)7 and
(TG)3TA(TG)nTA(TG)3, which were previously described by Chen
et al., were screened for polymorphic microsatellite alleles. The
region from c.*127 to c.*395 (from 932 to 1199 bp relative to the
transcription start site of FGF9), was ampliﬁed and sequenced as
described by Chen et al. [17].
2.5. In silico analysis
The DMRT1 variants c.774G>C and c.968-15insTTCTCTCT were
analysed in silico using the Human Splicing Finder prediction
program (HSF; http://www.umd.be/HSF/).
2.6. Statistical analysis
The frequencies of allelic variants of DMRT1 and microsatellite
motifs in the 3’ UTR of FGF9 were compared between controls and
the study group using the Chi-square test for categorical samples. A
p value <0.05 was considered statistically signiﬁcant. All statistical
analyses were performed with SigmaStat for Windows (version
2.03; SPSS, Inc., San Rafael, CA, USA). Allele frequency analysis
Table 1
Synthetic probes used to evaluate the presence of dosage imbalance in FGF9 in 46,XY gonadal dysgenesis patients.
Probes Size
(bp)
Probe 50a Probe 30b UCSC positionc Chr Region
GABRA 84 CAGCCTGTTGTCATAACCATCG AGCAAACTGTCCAGGATGCG 46994861e46994902 4p12
FGF9 e Exon2 94 CTCCCTTAGGTGAAGTTGGGAACTATTTCGGTGTG CAGGATGCGGTACCGTTTGGGAAT 22246056e22246114 13q11-q12
FGF9 e Exon 1 101 AGTGGACTCTACCTCGGGATGAATGAGA AGGGGGAGCTGTATGGATCAGTAA 22255237e22255288 13q11-q12
FGF9 e Exon 3 112 ACCTATATAAGCACGTGGACACTGGAAGGCGATAC TATGTTGCATTAAATAAAGATGGGA
CCCCGAGAGA
22275399e22275468 13q11-q12
MPDZ 123 GTGATCCAGTACTTGATCTGCATATGTCTCTGGAGGACT ATATACCCAGAATCTCCTGCAAAGA
CAGGATGAGAATACAC
13176317e13176397 9p23
RB1 129 GTCACCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTT AGTTCACCCTTACGGATTCCTGGAG
GAACATCTATATTTCACC
49039352e49039438 13q14.2
UHRF2 132 GTACGAGAGAATGTACTATTGTCCCTTCTAATCATTATGGACC
CATTC
CTGGTATTCCTGTTGGATCAACTTG
GAGATTTAGAGTTCAGG
6482011e6482100 9p24.1
a The 50 probe is always preceded by a universal primer attached to the sequence (GGGTTCCTAAGGGTTGGA).
b The 30 probe is always nested in a universal primer attached to the sequence (TCTAGATTGGATCTTGCTGGCAC), and its 50 end is phosphorylated.
c UCSC assembly: February 2009. The numbers indicate the coordinate of the ﬁrst base of the 50 probe and the last base of the 30 probe. Chr, chromosome.
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showed that all polymorphisms of DMRT1 were in Hardye
Weinberg equilibrium.
3. Results
3.1. DMRT1 and FGF9 gene dosage imbalance
No DMRT1 and FGF9 deletions or ampliﬁcations were identiﬁed
by the MLPA technique in the 33 patients studied.
3.2. DMRT1 and FGF9 allelic variants
Eight allelic variants of DMRT1 were identiﬁed, seven of them
had been previously described (Ensembl and NCBI) (Table 2). The
effects of the DMRT1 variants c.968-15insTTCTCTCT and c.774G>C
(rs146975077) on splice site selection were analysed in silico using
the web-based program HSF.
The HSF analysis suggested that the novel variant c.968-
15insTTCTCTCT, located in intron 4, may be able to cause the
insertion of a mutant silencer motif sequence, which could result in
a premature termination codon and a truncated protein (Fig. 1).
ThisDMRT1 variant was found in 6% of the patient alleles and in 12%
of the control alleles (Table 3).
A single copy of the c.774G>C (rs146975077)DMRT1 variantwas
identiﬁed in one patient with 46,XYpartial GD andwas not found in
control subjects. The analysis of the c.774G>C variant using HSF
suggested that this change might create a novel site in the Exonic
Splicing Enhancer (ESE) region, with a potentially deleterious effect
on the DMRT1 protein. This DMRT1 variant was reported to have
a prevalence of 2.8% in the African population in the 1000Genomes
database.
The c.*11_*12insT (rs11290071) variant was identiﬁed in 9
alleles of 33 patients with 46,XY GD (13.5%) and in 12 alleles of the
89 controls 6.7% (Table 3).
Nine allelic variants of FGF9, all previously described (Ensembl
and NCBI), were identiﬁed in this group of patients with 46,XY
gonadal dysgenesis (Table 2).
The microsatellite motif in the 3’ UTR is composed of two repeat
sequences, (GA)3(AG)2(GA)7 and (TG)3TA(TG)nTA(TG)3. The ﬁrst
repeat sequence was not polymorphic in our cohort, while six
different alleles (TG)13e18 of the second repeat sequence were
found (c.*275TGn). We analysed the distribution of the polymorphic
alleles between patients with 46,XYgonadal dysgenesis and control
males (Table 4).
4. Discussion
Recent insights into the mechanisms involved in the trans-
formation of undifferentiated gonadal tissue to organs with speci-
alised functions have revealed several essential genes in this
process: Sry/Dmrt1, Sox9, Fgf9/Pdg2 and Wnt4/Rspo1.
The Dmrt1 gene is a very important factor in inducing male sex
determination in invertebrates and vertebrates. Dmrt1 might
function as the ﬁrst signal of the male gonadal cascade in animals
whose sex determination is dependent on environmental factors.
Moreover, in male mice, the involvement of Dmrt1 in early male
gonadogenesis has been well demonstrated in knockout animals
[18,19].
However, the role of DMRT1 in testicular development in
humans has not yet been completely elucidated. Although
comparative genomic hybridization (CGH) and array CGH tech-
niques, powerful tools for the detection of minor chromosomal
imbalances, have been used to investigate 46,XY GD patients,
DMRT1 deletion has rarely been identiﬁed in patients without
syndromic features [9,20].
In this cohort of 46,XY patients with abnormal gonadal devel-
opment, the absence of DMRT1 dosage imbalances was identiﬁed
by MLPA analysis, conﬁrming the previous reports that submicro-
scopic deletions of DMRT1 are uncommon in non-syndromic 46,XY
GD patients.
Several DMRT1 polymorphisms have been described, and some
of these polymorphisms have been associated with an increased
risk of testicular germ cell tumour development in humans [21,22].
Although the HSF analysis had suggested that the novel c.968-
15insTTCTCTCT variant and the c.774G>C (rs146975077) variant
had potentially deleterious effects on the DMRT1 protein, the
distribution of the c.774G>C (rs146975077) allelic variant did not
show signiﬁcant differences between 46,XY GD patients and
controls (Table 3).
Table 2
Allelic variants in DMRT1 and FGF9 found in a cohort of 33 patients with 46,XY DSD.
Allelic variants Ensemble/NCBI reference Frequency (%)
DMRT1
c.-14C>T rs3739584 12.1
c.133A>T rs3739583 12.1
c.663T>C rs16925431 4.5
c.774G>C rs146975077 1.5
c.783C>T rs34946058 1.5
c.968-15insTTCTCTCT nv 6.06
c.1037A>G rs35846503 1.5
c.*11_*12insT rs112920071 13.6
FGF9
c.-125_-124 ins TT e 27.3
c.-124 ins T rs 35931146 39.4
c.278-28 T>C rs 17070202 18.2
c.278 -14 C>T rs 3818460 45.4
c.327 C>T (G109G) rs 34748315 27.3
c.309 C>T (G103G) rs 17070218 3.0
c.381þ 17C>T rs 2274296 2.2
c.447 A>G (S149S) rs 9509841 75.7
c.*9G>A rs 9509842 96.9
nv, Novel variant.
Fig. 1. Chromatogram of the novel variant c.968-15insTCTCTCT in the DMRT1 gene. The
beginning of 5 exon is indicated by black arrow.
Table 3
Allelic distribution of DMRT1 polymorphisms.
Allele Patients
(n¼ 33)
Control group
(n¼ 89)
Chi-square P value
c.-14C>T 8 36 1.626 0.202
c.133A>T 8 36 1.626 0.202
c.663T>C 3 2 1.363 0.243
c.774G>C 1 0 0.271 0.602
c.783C>T 1 2 0.166 0.684
c.968-15insTTCTCTCT 4 22 1.400 0.237
c.1037A>G 1 2 0.166 0.684
(c.*11_*12insT) -T 9 12 2.099 0.147
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The c.*11_*12insT variant, previously identiﬁed in a 46,XY
partial GD patient by Mello et al. [23], was found in this cohort of
patients (9 of 33 patients) but also in the control subjects (12 of 89
individuals). Statistical analysis indicated that this variant was not
signiﬁcantly more prevalent in the patient group (Table 3).
Although the role of Fgf9 in male gonadal development has been
well established in animal models, few studies in humans are
available. Until now, the only mutation identiﬁed in FGF9 was
p.Ser99Asn, which was identiﬁed in several members of a ﬁve-
generation Chinese family with multiple synostosis syndrome.
However, neither the genital characteristics nor the gonadal func-
tion of the 15 affected members of that family (six 46,XX and nine
46,XY) were described [24].
In addition, several FGF9 polymorphisms are described on the
Ensembl database (www.ensembl.org). In our cohort of 33 patients
with non-syndromic 46,XY GD, we identiﬁed nine allelic variants
with frequencies similar to those found in previous reports. In 2007,
Chen et al. studied the coding and untranslated regions of FGF9 and
identiﬁed microsatellites in the 3’ UTR of FGF9, the (TG)n motif.
They identiﬁed four different alleles, (TG13e16) (c.*275TG)n. The
(TG)14 motif was identiﬁed in their patients with 46,XY DSD of
different aetiologies and rarely in controls (P¼ 0.01). Functional
studies demonstrated that the (TG)14 allele had the greatest
promoter activity in luciferase expression assays and also longer
mRNA stability than the other alleles [17].
Based on these ﬁndings, the authors suggested that the 3’UTR
FGF9 microsatellite (TG)14 allele is a functional polymorphism that
may inﬂuence the risk of human 46,XY DSD by altering the regu-
lation of FGF9 expression both pre- and post-transcriptionally.
Our study of the 3’ UTR microsatellite region of FGF9 in a cohort
consisting exclusively of patients with 46,XY GD did not conﬁrm
the previously reported results. Six different alleles (TG)13e18
(c.*275TGn) in the 3’ UTR of FGF9 were identiﬁed in our patients,
but none of them, including the (TG)14 allele, was statistically
associated with the presence of gonadal dysgenesis (Table 4). The
heterogeneous 46,XY DSD aetiologies of the patients described by
Chen et al. may have contributed to the difference in results.
The mechanisms responsible for the regulation of FGF9
expression are poorly understood. An adenylate/uridylate-rich
element (ARE) in the FGF9 3’UTR was recently shown to be
crucial in the control of FGF9 expression [25]. Mutations in these
regulatory elements might cause a reduction in FGF9 expression
and secondarily might affect normal male gonadal development.
The effects of speciﬁc regulatory elements on FGF9 expression and
their possible consequences for testicular development must be
better evaluated.
In conclusion, this study suggests that complete or partial
deletions and inactivating mutations of DMRT1 and FGF9 are not
frequently found in 46,XY DSD patients with abnormal gonadal
development. Moreover, the DMRT1 and FGF9 allelic variants
identiﬁed in this cohort of patients had apparently no association
with gonadal dysgenesis. Whole genome, exome sequencing and
array comparative genomic hybridization analysis could be useful
tools for the molecular diagnosis of XY GD by the identiﬁcation of
potential candidate genes, and elucidation of the real role of DMRT1
and FGF9 in male sexual development.
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